Welcome to ProNoxis

ProNoxis AB was founded in 2009 by LU Bioscience AB (LUBio), Karolinska Development AB, and Redoxis AB, as a Redoxis spin-off focusing on developing anti-inflammatory therapeutics targeting activation of the NADPH oxidase complex (NOX2). Since 2012 it is wholly owned by Redoxis AB.

ProNoxis focuses on the development of small-molecule drugs to treat chronic inflammation.